Acrivastine versus hydroxyzine in the treatment of cholinergic urticaria. A placebo-controlled study

• Published in: Acta dermato-venereologica Vol. 68; no. 6; pp. 541 - 544
• Main Authors: BLACK, A. K, ABOOBAKER, J, GIBSON, J. R, HARVEY, S. G, MARS, P
• Format: Journal Article
• Language: English
• Published: Uppsala Acta dermato-venereologica 1988
• Subjects: Adult; Aged; Biological and medical sciences; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Exercise; Female; Histamine and antagonists. Allergy; Histamine H1 Antagonists - therapeutic use; Humans; Hydroxyzine - therapeutic use; Male; Medical sciences; Middle Aged; Peak Expiratory Flow Rate; Pharmacology. Drug treatments; Placebos; Pyridines - therapeutic use; Triprolidine - analogs & derivatives; Triprolidine - therapeutic use; Urticaria - drug therapy; Immunopathology; Chemotherapy; Skin disease; Cholinergic urticaria; Comparative study
• ISSN: 0001-5555; 1651-2057

Ten patients with cholinergic urticaria (CU) were entered into a double-blind, placebo-controlled, cross-over study. They were scheduled to receive acrivastine 8 mg t.d.s., hydroxyzine hydrochloride 20 mg t.d.s. and placebo according to a fully randomized, balanced treatment plan. Subjective clinical assessments and objective measurements following exercise challenge were performed during the study period. Both acrivastine and hydroxyzine were shown to be effective and well tolerated in the treatment of cholinergic urticaria. In addition, a trend was demonstrated for both active agents to improve peak expiratory flow rate (PEFR) following exercise, when compared with placebo, and this trend reached statistical significance in the case of acrivastine (p less than 0.05).